IL277333B1 - Vegf antagonists for use in treating diabetic macular edema - Google Patents

Vegf antagonists for use in treating diabetic macular edema

Info

Publication number
IL277333B1
IL277333B1 IL277333A IL27733320A IL277333B1 IL 277333 B1 IL277333 B1 IL 277333B1 IL 277333 A IL277333 A IL 277333A IL 27733320 A IL27733320 A IL 27733320A IL 277333 B1 IL277333 B1 IL 277333B1
Authority
IL
Israel
Prior art keywords
patient
weeks
vegf antagonist
regimen
use according
Prior art date
Application number
IL277333A
Other languages
Hebrew (he)
Other versions
IL277333A (en
IL277333B2 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL277333A publication Critical patent/IL277333A/en
Publication of IL277333B1 publication Critical patent/IL277333B1/en
Publication of IL277333B2 publication Critical patent/IL277333B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Description

277333/ VEGF ANTAGONISTS FOR USE IN TREATING DIABETIC MACULAR EDEMA FIELD OF THE INVENTION The invention relates to methods for treating ocular disease with a VEGF antagonist. In particular, the invention relates to treating diabetic macular edema with less frequent dosing than currently approved treatment regimens.
BACKGROUND OF THE INVENTION Diabetes mellitus (DM) is the most common endocrine disease in developed countries, with prevalence estimates ranging between 2 to 5% of the world population. Diabetic retinopathy (DR) and diabetic macular edema (DME) are common microvascular complications in patients with diabetes and may have a debilitating impact on visual acuity (VA), eventually leading to blindness. DME is a frequent manifestation of DR (Riordan-Eva, 2004, Eye (Lond). 2004, 18:1161-8) and is the major cause of visual loss in patients with DR.
For anti-VEGF agents like ranibizumab or aflibercept a favorable benefit risk ratio was demonstrated with superior efficacy versus the previous standard of care (laser photocoagulation) in large Phase 3 programs that consequently led to their approval for the treatment of DME. Anti-VEGF treatment led to clinically relevant improvements of BCVA, reduction of fluid accumulation and decreased severity of diabetic retinopathy.
The current treatment options for patients with DME are: laser photocoagulation, intravitreal (IVT) corticosteroids, IVT corticosteroid implants, or IVT anti-VEGF therapeutic. Due to the efficacy and safety profile of anti-VEGF therapy, it has become the first-line treatment. Corticosteroids are used as a second line treatment and focal / grid laser photocoagulation remains a therapeutic option, but with a lower expected benefit compared with steroid and anti-VEGF therapy.
Despite the treatment success of existing anti-VEGFs, there remains a need for further treatment options to improve response rate and/or reduce resource use and injection frequency in patients with DME (Mitchell et al., 2011, Ophthalmology 118(4):615-25; Smiddy, 2011, Ophthalmology 118(9):1827–33; Lang et al., 2013, Ophthalmology 120(10):2004-12; Virgili et al., 2014, Br J Ophthalmol 98(4):421-2; Agarwal et al., 2015, Curr Diab Rep. 15(10):75).

Claims (8)

1. 277333/ CLAIMS 1. A VEGF antagonist for use in a method of treating diabetic macular edema (DME) in a patient, the method comprising: a) administering to the patient five individual 6 mg doses of brolucizumab at 6- week intervals, ending at week 24; b) administering to the patient additional doses of brolucizumab once every weeks (q8w regimen) starting at week 32, or once every 12 weeks (q12w regimen) starting at week 36; c) assessing the patient’s disease activity at weeks 32, 36, 48, 60, and 72, if disease activity is identified at any of the assessments, the patient is assigned to receive a q8w regimen, and d) at week 72 the patient’s q12w regimen can be extended by 4 weeks, to a q16w regimen, or the patient’s q8w regimen can be extended by 4 weeks, to a q12w regimen, if the patient’s disease activity is not worsening for multiple consecutive assessments, wherein the disease activity is assessed for relevant improvements of BCVA, reduction of central subfield thickness (CST), reduction of fluid accumulation, or decreased severity of diabetic retinopathy.
2. The VEGF antagonist for use according to claim 1, wherein if worsening of DME disease activity is identified after a q12w dose, the patient is switched to a q8w regimen, wherein the additional doses are administered once every 8 weeks instead of once every 12 weeks.
3. The VEGF antagonist for use according to claim 1, wherein if worsening of DME disease activity is identified after a q16w dose, the patient is switched to a q12w or q8w regimen, wherein the additional doses are administered once every 12 weeks or every 8 weeks instead of once every 16 weeks.
4. The VEGF antagonist for use according to claim 2 or 3, wherein the worsening of DME disease activity is a loss of letters in best corrected visual acuity (BCVA), increased central subfield thickness (CST), and/or increased fluid accumulation compared to any previous assessment. 277333/
5. The VEGF antagonist for use according to any one of claims 1-4, wherein the VEGF antagonist is administered by intravitreal injection.
6. The VEGF antagonist for use according to any one of claims 1-5, wherein the concentration of brolucizumab is about 60, 70, 80, 90, 100, 110, or 120 mg/ml.
7. The VEGF antagonist for use according to any one of claims 1-6, wherein each dose of the VEGF antagonist is 3 mg or 6 mg.
8. The VEGF antagonist for use according to claims 5-7, wherein each dose of the VEGF antagonist is administered as a 50 µL intravitreal injection.
IL277333A 2018-03-16 2019-03-08 Vegf antagonists for use in treating diabetic macular edema IL277333B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862643887P 2018-03-16 2018-03-16
US201962805344P 2019-02-14 2019-02-14
PCT/IB2019/051899 WO2019175727A1 (en) 2018-03-16 2019-03-08 Methods for treating ocular diseases

Publications (3)

Publication Number Publication Date
IL277333A IL277333A (en) 2020-10-29
IL277333B1 true IL277333B1 (en) 2025-11-01
IL277333B2 IL277333B2 (en) 2026-03-01

Family

ID=66049363

Family Applications (2)

Application Number Title Priority Date Filing Date
IL277333A IL277333B2 (en) 2018-03-16 2019-03-08 Vegf antagonists for use in treating diabetic macular edema
IL323849A IL323849A (en) 2018-03-16 2025-10-09 VEGF antagonists for use in the treatment of diabetic macular edema

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL323849A IL323849A (en) 2018-03-16 2025-10-09 VEGF antagonists for use in the treatment of diabetic macular edema

Country Status (11)

Country Link
US (1) US20210017266A1 (en)
EP (1) EP3765083A1 (en)
JP (3) JP6938796B2 (en)
KR (2) KR20260036043A (en)
CN (1) CN111867631A (en)
AU (2) AU2019235577B2 (en)
CA (1) CA3091096A1 (en)
IL (2) IL277333B2 (en)
MX (1) MX2020009140A (en)
TW (1) TWI727279B (en)
WO (1) WO2019175727A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (en) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Antibodies that bind to human protein tyrosine phosphatase beta (HPTP-beta) and their uses
KR20180005753A (en) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Stable and soluble antibodies inhibiting vegf
RU2653753C1 (en) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
PL2307458T3 (en) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
MX363351B (en) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Methods for treating vascular leak syndrome and cancer.
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
TWI806150B (en) 2014-11-07 2023-06-21 瑞士商諾華公司 Stable protein solution formulation containing high concentration of an anti-vegf antibody
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and conjugates thereof
KR20190130608A (en) 2017-03-22 2019-11-22 노파르티스 아게 Compositions and Methods for Immune Oncology
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
MX2020009140A (en) * 2018-03-16 2020-09-28 Novartis Ag Methods for treating ocular diseases.
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES TARGETING HPTP-ß (VE-PTP) AND VEGF
CN113194993A (en) 2018-12-18 2021-07-30 诺华股份有限公司 Protein solution formulations containing high concentrations of anti-VEGF antibodies
PE20240329A1 (en) 2019-06-05 2024-02-27 Regeneron Pharma DEVICES AND METHODS FOR PRECISION DOSE ADMINISTRATION
AU2020347575A1 (en) 2019-09-13 2022-03-17 Novartis Ag Methods for treating ocular diseases
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3171563A1 (en) 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor
WO2022066788A1 (en) * 2020-09-23 2022-03-31 Genentech, Inc. Machine learning prediction of injection frequency in patients with macular edema
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
JP2026520094A (en) 2023-04-11 2026-06-22 オキュラ セラピューティクス,インコーポレイテッド Ophthalmic implants including axitinib polymorphic IV

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160340420A1 (en) * 2014-11-07 2016-11-24 Novartis Ag Stable protein solution formulation containing high concentration of an anti-vegf antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802334E (en) 2004-10-21 2012-11-28 Genentech Inc Method for treating intraocular neovascular diseases
KR20180005753A (en) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Stable and soluble antibodies inhibiting vegf
KR20180023015A (en) * 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. Use of a vegf antagonist to treat angiogenic eye disorders
WO2014033184A1 (en) * 2012-08-28 2014-03-06 Novartis Ag Use of a vegf antagonist in treating ocular vascular proliferative diseases
JP6959912B2 (en) * 2015-09-23 2021-11-05 ジェネンテック, インコーポレイテッド Optimized variant of anti-VEGF antibody
MX2020009140A (en) * 2018-03-16 2020-09-28 Novartis Ag Methods for treating ocular diseases.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160340420A1 (en) * 2014-11-07 2016-11-24 Novartis Ag Stable protein solution formulation containing high concentration of an anti-vegf antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEIER JEFFREY S ET AL,, INTRAVITREAL AFLIBERCEPT FOR DIABETIC MACULAR EDEMA 148-WEEK RESULTS FROM THE VISTA AND VIVID STUDIES, 17 September 2016 (2016-09-17) *
LALLY ET AL.,, VASCULAR ENDOTHELIAL GROWTH FACTOR AND DIABETIC MACULAR EDEMA. SURVEY OF OPHTHALMOLOGY, 26 October 2016 (2016-10-26) *

Also Published As

Publication number Publication date
IL277333A (en) 2020-10-29
JP2021509912A (en) 2021-04-08
IL277333B2 (en) 2026-03-01
JP6938796B2 (en) 2021-09-22
IL323849A (en) 2025-12-01
EP3765083A1 (en) 2021-01-20
TWI727279B (en) 2021-05-11
AU2021286278B2 (en) 2023-09-14
WO2019175727A1 (en) 2019-09-19
KR20200131839A (en) 2020-11-24
TW201945027A (en) 2019-12-01
AU2021286278A1 (en) 2022-01-20
RU2020133816A (en) 2022-04-18
RU2020133816A3 (en) 2022-04-18
KR20260036043A (en) 2026-03-13
JP2021191778A (en) 2021-12-16
AU2019235577A1 (en) 2020-08-27
AU2021286278C1 (en) 2024-05-23
MX2020009140A (en) 2020-09-28
CA3091096A1 (en) 2019-09-19
US20210017266A1 (en) 2021-01-21
AU2019235577B2 (en) 2021-09-30
CN111867631A (en) 2020-10-30
JP2024042697A (en) 2024-03-28

Similar Documents

Publication Publication Date Title
IL323849A (en) VEGF antagonists for use in the treatment of diabetic macular edema
Ishibashi et al. The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema
Sun et al. Rationale and application of the protocol S anti–vascular endothelial growth factor algorithm for proliferative diabetic retinopathy
Mitchell et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema
Faghihi et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema
Freund et al. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab
Kourlas et al. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review
Schmidt-Erfurth et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study
Ciulla et al. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration
Frampton Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration
JP2021004262A (en) Treatment of age related macular degeneration with small active choroidal neovascularization lesion
RU2572707C2 (en) Ophthalmic drops with difluprednate for treating macular oedema
Jiang et al. Update on the use of anti-VEGF intravitreal therapies for retinal vein occlusion
Shah et al. Does laser still have a role in the management of retinal vascular and neovascular diseases?
Özdek et al. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema
Lightman et al. Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis
JP6944958B2 (en) Use of sirolimus for the treatment of exudative age-related macular degeneration with persistent edema
Samanta et al. Emerging therapies in nonexudative age-related macular degeneration in 2020
JP7176960B2 (en) Salbutamol-containing ophthalmic medicine
Heier et al. Intravitreal combined aflibercept+ anti–platelet-derived growth factor receptor β for neovascular age-related macular degeneration: results of the phase 2 CAPELLA trial
Tano et al. EXTEND‐I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration
Moon et al. Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis
Okhotsimskaya et al. Aflibercept for the therapy of retinal diseases. A review of clinical studies
Do Antiangiogenic approaches to age-related macular degeneration in the future
Yalcinbayir et al. Intravitreal versus sub-tenon posterior triamcinolone injection in bilateral diffuse diabetic macular edema